In a groundbreaking development, the FDA has granted approval for the Teal Wand, a home screening device for cervical cancer by Teal Health. This innovative device allows users to self-collect samples for laboratory analysis, providing the same testing as in a clinical setting.
Teal Health secured $10 million in a seed extension round earlier this year, totalling $23 million in funding so far, with notable investors such as Serena Ventures and Chelsea Clinton. The company aims to address the reluctance many women feel towards undergoing cervical cancer screenings, which are critical for detecting the disease early. Kara Egan, co-founder and CEO, emphasises the importance of these screenings, noting that over a quarter of women are currently overdue for their essential tests.
Historically, cervical cancer was one of the most prevalent cancers among women. However, increased screening and preventive measures have led to a decline in cases, as reported by the American Cancer Society. The Teal Wand kit will include the self-collection device and offer virtual consultations with medical professionals to discuss lab results. Initially, these kits will be available from June, commencing in California.
Fanpage:Â TechArena.au
Watch more about AI – Artificial Intelligence
